1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

York Pharma completes acquisition from Solvay

 
• By Simon Varcoe

York Pharmahas completed its €28.5 million acquisition of the dermatological and wound care products Flammazine and Flammacerium from[C#198600973:Solvay] Pharmaceuticals. [C#198600973:Solvay] will receive €17 million up-front and an additional €11.5 million by the end of the year. Flammazine and Flammacerium, both of which contain silver sulfadiazine, are sold in 21 countries and have annual sales of around £8.5 million.

York Pharmahas completed its €28.5 million acquisition of the dermatological and wound care products Flammazine and Flammacerium fromSolvay Pharmaceuticals. Solvay will receive €17 million up-front and an additional €11.5 million by the end of the year. Flammazine and Flammacerium, both of which contain silver sulfadiazine, are sold in 21 countries and have annual sales of around £8.5 million.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapeutic Category

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.